Improving prognosis in type 2 diabetes: Diabetic neuropathy is in trouble

Diabetes Care

Volumn 22, Issue SUPPL. 2, 1999, Pages

  Ward, John Dale ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ESSENTIAL FATTY ACID; GROWTH FACTOR; NEUROTROPHIC FACTOR;

ANALGESIA; BLOOD GLUCOSE MONITORING; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; HUMAN; MICROVASCULATURE; NERVE; NERVE FUNCTION; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; TEMPERATURE SENSE; VIBRATION SENSE;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FATTY ACIDS, ESSENTIAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NERVE GROWTH FACTORS; OXIDATIVE STRESS; PALLIATIVE CARE; PROGNOSIS; SURAL NERVE;

EID: 0033016899     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Young MJ, Boulton AJ, Macleod AF, Williams DR, Sonksen PH: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150-154, 1993
2. Veves A, Webster L, Chen TF, Payne S, Boulton AJM: Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic. Diabet Med 12:77-82, 1995
3. Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: ten years experience in diabetes. Diabetes Care 8:491-498, 1985
4. Rathmann W, Zeigler D, Jahnke M, Haastert B, Gries FA: Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 10:820-824, 1993
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561-568, 1995
6. Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ: Improved survival of the diabetic foot: the role of a specialised foot clinic. Q J Med 232:763-771, 1986
7. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21:1071-1075, 1998
8. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37:589-596, 1987
9. Thomas PK, Ward JD: Diabetic neuropathy. In Complications of Diabetes. Keene H, Jarrett J, Arnold E, Eds. London, Edward Arnold, 1975, p. 151-178
10. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD, the EURODIAB IDDM Study Group: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 39:1377-1384, 1996
11. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Ann Neurol 38:478-482, 1995
12. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17:1281-1289, 1994
13. Valk GD, Nauta IJP, Stijers RJM, Bertlesmann FW: Clinical examination versus neurophysiological examination in the diagnosis of diabetic neuropathy. Diabet Med 9:716-721, 1992
14. Veves A, Malik RA, Lye RH, Masson EA, Sharma AK. Schady W, Boulton AJ: The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy. Diabet Med 8:917-921, 1991
15. Oates PJ: The polyol pathway: a culprit in diabetic neuropathy. Neurosci Res Commun. In press
16. Boulton AJ, Kubrusly DB, Bowker JH, Gadia MT, Quintero L, Becker DM, Skyler JS, Sosenko JM: Impaired vibratory perception and diabetic foot ulceration. Diabet Med 3:335-337, 1986
17. Valensi P, Atalli JR, Cagant S, the French Group for Research and Study of Diabetic Neuropathy: Reproducibility of parameters for assessment of diabetic neuropathy. Diabet Med 10:933-939, 1993
18. Greene DA, Arezzo J, Brown M, the Zenarestat Study Group: Dose-related effects of the aldose reductase inhibitor Zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fibre density in human diabetic neuropathy (Abstract). Diabetes 45 (Suppl. 2):5A, 1996
19. Ward JD: Upright posture and the microvasculature in human diabetic neuropathy: a hypothesis. Diabetes 46 (Suppl. 2):94-97, 1997
20. Cotter MA, Cameron NE: The aetiopathogenesis of diabetic neuropathy metabolic theories. In Diabetic Neuropathy. Boulton AJM, Ed. Camforth, Lancashire, U.K., Marius Press, 1997, p. 97-146
21. Greene DA: Effects of aldose reductase inhibitors on the progression of nerve damage in diabetic neuropathy. J Diabet Complications 6:35-38, 1992
22. Brownlee M: Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-1843, 1992
23. Low PA, Nickander KK: Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-877, 1991
24. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37:449-459, 1994
25. Cameron NE, Cotter MA, Maxfield EK: Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats Diabetologia 36:299-304, 1993
26. Cameron NE, Cotter MA: Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway activity. Diabetologia 35:1011-1019, 1992
27. Horrobin DF, Carmichael HA: Essential fatty acids in relation to diabetes. In Treatment of Diabetic Neuropathy: A New Approach. Horrobin DF, Ed. London, Churchill Livingstone, 1992, p. 21-39
28. Cameron NE, Cotter MA, Robertson S: Essential fatty acid diet supplementation: Effects on peripheral nerve and skeletal muscle function and capillarisation in streptozotocin-induced diabetic rats. Diabetologia 40:532-539, 1991
29. The Gamma-Linolenic Acid Multi-Centre Trial Group: Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 16:8-15, 1993
30. Cameron NE, Cotter MA: Comparison of the effects of ascorbyl gamma linolenic acid and gamma-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetologia 39:1047-1054, 1996
31. Ishii DN: Implications of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 20:47-65, 1995
32. Zhuang H-X, Snyder CK, Pu S-F, Ishii D N: Insulin-like growth factors reverse or arrest diabetic neuropathy in rats: effects on hyperalgesia and impaired nerve regeneration. Exp Neurol 140:198-205, 1996
33. Migdalis TN, Kalogeropoulou K, Kalantzis L, Nounopoulos C, Bouloukos A, Samartzis M: Insulin-like growth factor-1 and IGF-1 receptors in diabetic patients with neuropathy. Diabet Med 12:823-827, 1995
34. Tesfaye S, Malik R, Ward JD: Vascular factors in diabetic neuropathy. Diabetologia 37:847-854, 1994
35. Malik RA, Newrick PG, Sharma AK, Jennings A, Ah-See AK, Mayhew TM, Jakubowski JJ, Boulton AJM, Ward JD: Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the seventy of neuropathy. Diabetologia 32:92-102, 1989
36. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJ, Ward JD: Sural nerve oxygen tension in diabetes. Br Med J 293:1053-1054, 1986
37. Tesfaye S, Harris N, Jakubowski JJ, Mody C, Wilson RM, Rennie IG, Ward JD: Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 36:1266-1274, 1993
38. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, Ward JD: Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 37:847-854, 1996
39. Le Quesne P, Fowler CJ: A study of pain threshold in diabetics with neuropathic foot lesions. J Neurol Neurosurg Psychiatr 49:1191-1194, 1986